Magnesium influence on morphine--induced pharmacodependence in rats.
We tested Mg2+ influence on experimental morphine-induced pharmacodependence in rats. Morphine-induced pharmacodependence model consists of progressively increased doses of morphine (M) (5 mg/kg i.p. until 90 mg/kg i.p.) during 10 days. Withdrawal syndrome was induced by naloxone (N) administration (1 mg/kg, s.c.) on the 11th day, 2 h after the last morphine administration. We evaluated and statistically interpreted symptoms from withdrawal syndrome. 2 groups received magnesium acetate (MgAc) 0.5 mEq/kg/day i.p. and 0.1 mEq/kg/day MgAc i.p. respectively during all 11 days of morphine-induced pharmacodependence. Serum magnesium levels were determined by spectrophotometry. Data obtained show that MgAc significantly decreases symptoms from withdrawal syndrome (grooming 19.9 +/- 2.1 in M + MgAc 0.5 mEq/kg/day vs. 33 +/- 2.85 in M group, p < 0.01).
Nechifor
Mihai
M
Department of Pharmacology, University of Medicine and Pharmacy Gr. T. Popa, Universitatii 16, Iasi 6600, Romania. nechifor@umfiasi.ro
Chelarescu
Dan
D
Miftode
Maria
M
D000085:Acetates / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight; D004305:Dose-Response Relationship, Drug; D008274:Magnesium / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D008954:Models, Biological; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence; D009270:Naloxone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D000085:Acetates; D000701:Analgesics, Opioid; D009270:Naloxone; D009020:Morphine; D008274:Magnesium